Metabolomics and chemosensitivity
This project investigates the role of stromal cells in the development of chemoresistance in pancreatic cancer cells.
About the project
Despite treatment advances, PDAC has a dismal 5-year survival rate (<7%). The failure to translate the effects of existing therapeutics into better survival benefits for patient with pancreatic ductal adenocarcinoma (PDAC) is mainly linked to the development of treatment resistance.
The experiments are based on primary cultures of human PDAC-derived cancer cells and PSCs and tumor tissue biopsies. In this project, multiomics techniques including genomics, proteomics, metabolomics and lipidomics are employed.
- Lars O. Dragsted, University of Copenhagen, Denmark
- Jan Borén, University of Gothenburg, Sweden
- University of Oslo
South-Eastern Norway Regional Health Authority (HSØ), project nr. 2020062
- 2018 - ongoing